GlassScriptPhysician profile
Douglas S Black
NPI 1033108196
$6,751.15
in general payments reported to CMS, 2019-2025
33 companies · $748 in 2025
The $748 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $664 · 2021: $992 · 2022: $1,595 · 2023: $857 · 2024: $716 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Debt Forgiveness: $158 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.99 |
| Debt Forgiveness | $157.73 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,013.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.44 | 2019-2025 | Jardiance |
| Baxter Healthcare | $663.84 | 2022-2024 | |
| Pfizer INC. | $501.91 | 2019-2025 | |
| Boston Scientific Corporation | $500.79 | 2019-2025 | Emblem Mri S-Icd, General - Brady, Vigilant X4 Crt-D |
| Janssen Pharmaceuticals, INC | $477.80 | 2019-2024 | Xarelto |
| Abiomed | $441.69 | 2020-2025 | Impella |
| Merck Sharp & Dohme LLC | $413.76 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.36 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $317.93 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $264.95 | 2019-2021 | |
| Amarin Pharma, INC. | $150.25 | 2019-2021 | |
| Biotronik INC. | $124.92 | 2019-2024 | Acticor 7 Vr-T Dx, Biomonitor |
| Abbott Laboratories | $117.40 | 2019-2023 | Mitraclip |
| Medtronic, INC. | $112.43 | 2022-2023 | Onyx Frontier |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $82.64 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Astrazeneca Pharmaceuticals LP | $70.98 | 2019-2021 | |
| Gilead Sciences, INC. | $54.41 | 2019 | |
| Shockwave Medical, INC | $51.12 | 2025 | |
| Alnylam Pharmaceuticals INC. | $46.14 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $42.90 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $21.68 | 2024 | Opsumit, Uptravi |
| Medicomp INC | $21.05 | 2023 | Telepatch Cardiac Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Qorumpartners | $19.36 | 2022 | |
| Scpharmaceuticals INC. | $16.45 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $15.31 | 2024 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Philips North America LLC | $14.87 | 2025 | Ecc Solutions |
| Kowa Pharmaceuticals America, INC. | $14.40 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.21 | 2021 | |
| Esperion Therapeutics, INC. | $13.88 | 2020 | |
| Elutia, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.